Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23649271 | 0.98 | OPRL1 (0.40) | PKMPDE7AOPRL1OPRM1OPRD1 | |
| SCHEMBL4069650 | 0.94 | OPRL1 (0.40) | PKMPDE7AOPRL1OPRM1OPRD1 | |
| SCHEMBL30062630 | 0.89 | OPRL1 (0.42) | PDE7AOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL23232266 | 0.89 | OPRL1 (0.42) | PDE7AOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL29484741 | 0.80 | MEN1 (0.41) | PKMHDAC4ADORA3SIGMAR1AKR1C1 | |
| SCHEMBL17733195 | 0.80 | MEN1 (0.41) | PKMHDAC4ADORA3SIGMAR1AKR1C1 | |
| SCHEMBL6058582 | 0.80 | MEN1 (0.41) | PKMHDAC4ADORA3SIGMAR1AKR1C1 | |
| SCHEMBL6847429 | 0.80 | SIGMAR1 (0.57) | OPRL1OPRM1OPRD1OPRK1PDK2 | |
| SCHEMBL7101793 | 0.75 | OPRM1 (0.37) | OPRL1OPRM1OPRD1OPRK1PDK2 | |
| SCHEMBL6152505 | 0.75 | PDE7A (0.40) | PKMPDE7AOPRL1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2583958-B1 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2583958-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | Massachusetts Institute of Technology (MIT) (US) | 2013-04-24 | — | — | EP | disclosed |
| US-7560582-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560582-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080033171-A1 | Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080033171-A1 | Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-02-07 | — | — | US | disclosed |
| US-7247731-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247731-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-07-24 | — | — | US | disclosed |
| US-7223879-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223879-B2 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1354887-B1 | Ligands for metals and improved metal-catalyzed processes based thereon | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-04-25 | — | — | EP | disclosed |
| US-3979444-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES | THE UPJOHN COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033171-A1 | Ligands for Metals and Improved Metal-Catalyzed Processes Based Thereon | THEM6, SOD1, SLC30A6 | PKM 1089/4885PDE7A 4641/4885OPRL1 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.